70 Years of Scientific Research on Diseases (1947-2017) - number of research articles published (PubMed) # For more interesting & helpful content on healthcare & data science, follow me & Brainformatika on LinkedIn.

Corvidia Therapeutics Inc., a clinical stage biotechnology company, announced today the initiation of patient screening for a Phase 2b dose-finding study of ziltivekimab. Previously known as COR-001, ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD).

On behalf of AURP, and our BIO Health Caucus Co-Chairs Mark Romney and Rich Bendis, we would like to thank all who participated at the inaugural BIO Health Caucus, making it a grand success!

Each of our speakers and sessions shared significant insight into what is on the horizon for our global biomedical innovation district. Everyone's active presence was paramount in our ongoing mission to help the AURP community thrive. This gathering of bio-focused professionals served as an opportunity to establish, promote, and assemble health-related anchor institutions, creating new technologies, developing biotechnology partnerships, and improving health outcomes.

The next BIO Health Caucus will converge at the AURP IC2019 on November 5, 1:00 – 4:00 pm.

A vaccine for HIV. Nanoparticles. A topical ointment for sickle cell disease.

Those are just three examples of technologies discussed at a showcase held by the Frederick National Laboratory for Cancer Research and the National Cancer Institute.

Inova Center for Personalized Health, Fairfax You’re invited to spend the day with innovative entrepreneurs, professionals and industry leaders. Discover opportunities to help you navigate through a rapidly evolving modern industry & gain access to cutting edge technologies and tools.

Join forces with industry and academia leaders, researchers and decision-makers, all gathered together, at the same time, and at the same place, bringing ideas together to make a global impact and change the world.

Women Building Bio is where the future is transformed into reality.

You are invited to join Learning Undefeated as we expand our reach again and welcome three new mobile laboratories.

Drop Anywhere Labs are the newest innovation in mobile STEM education, custom-built shipping containers that serve as flexible laboratory and classroom space for middle and high schools. Tour all six of our mobile laboratories including Drop Anywhere Labs, the Mobile eXploration Lab, MdBioLab, and Verizon explorer lab.

Event Info

Date: Thursday, August 1, 2019

Time: 4:00 - 6:00 PM

MCEDC talks with Douglas Liu, SVP of Global Operations for Qiagen, about how his company makes improvements in life possible.

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations, today announced that it has strategically partnered with Columbia University to open Alexandria LaunchLabs®, the premier life science startup platform, at the university in the spring of 2020. Building upon the success of the flagship Alexandria LaunchLabs site at the Alexandria Center® for Life Science – New York City, Alexandria LaunchLabs @ Columbia will increasingly focus on promising life science startups emerging from Columbia and peer institutions, which serve as the greatest source of new company formation in the NYC life science ecosystem.

Hundreds of politicians, Capitol staff members, and campus top brass will gather on Wednesday in Washington to hear about researchers’ work. The scholars aren’t leaving any detail to chance.

Last week two new partnerships were formed between Maryland and the United Kingdom. Biohealth Innovation, a MD based public-private nonprofit focused on accelerating commercialization for biohealth, will be collaborating with Catalyze, an Amsterdam based company dedicated to bringing non-dilutive funding for biomedical innovations.

Andrew Lees, Ph.D., is founder and scientific director of Fina Biosolutions, LLC (Rockville, Md.), a company focused on promoting affordable conjugate vaccines by making the technology available to emerging market vaccine manufacturers. Among his contributions in the field, Lees developed an efficient linking chemistry which is widely used in conjugate vaccines, a class that includes vaccines for S. pneumoniae and meningococcal disease. The chemistry has helped to reduce the cost of these vaccines.  

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the first U.S. Food and Drug Administration (FDA) approval of a gene therapy that leverages REGENXBIO's proprietary NAV Technology Platform, Novartis AG's ZOLGENSMA® (onasemnogene abeparvovec-xioi; AVXS-101). ZOLGENSMA was approved by the FDA as a one-time infusion for pediatric patients with spinal muscular atrophy (SMA) who are less than two years of age.

How does the healthcare sector stack up on gender equality? To answer that question, we look at pipeline practices, employee experiences, and policies and programs the industry has implemented to promote diversity and inclusion. We also hear from industry leaders on what it takes to accelerate change across the sector.

A just-released study co-sponsored by the Biotechnology Innovation Organization (BIO) and AUTM provides new evidence of the significant contribution academic patent licensing makes to the U.S. economy. The report is the most recent in a series, and the numbers are astounding.

Gene therapies represent some of the most promising advancements in science and human health in recent history.  The BioHealth Capital Region, and Maryland in particular, is rapidly becoming a hub for companies in this field. With the NIH and the National Cancer Institute at the nucleus, some of the most advanced scientific research and technology development in the field is happening in a short 30-mile radius around Montgomery County, Maryland.

Ceres Nanosciences, Inc. (Ceres), University of Virginia (UVA), and George Mason University (Mason) today announced the receipt of a $600,000 award from the Virginia Catalyst for the development of a Nanotrap® liquid biopsy collection device. This award will be matched by $1.2 million in product development funding by Ceres Nanosciences.

Fortune 500 healthcare company Baxter International is planning to partner with a trio of Baltimore organizations.

The Chicago-based company plans to work with Johns Hopkins University, LifeBridge Health and the University of Maryland, Baltimore.

Maryland state delegate Lily Qi shares her path to becoming a first-generation Chinese-American lawmaker. Qi is from Shanghai.

BRAINBox Solutions today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's BRAINBox TBI (Traumatic Brain Injury) test in development, the first to aid in both the diagnosis and prognosis of mild TBI (concussion). The BRAINBox TBI test is a multi-modality, quantitative test that combines injury-related blood protein biomarkers with computerized neurological assessments.

At the molecular level, we may not age gracefully; that is, we may not follow a continuous, linear downward slope. Instead, we may fall precipitously after we lose control of our exquisitely balanced anti-aging programs, sometime in our 50s. These findings, derived from a study of tissue-coding and noncoding RNA, may help explain why human disease burden increases so sharply from the sixth decade of life onward. They may also lead to therapies that enhance longevity, provided the natural termination of protective gene expression patterns does not indicate that they have outlived their usefulness.

The new chairman of the Biotechnology Innovation Organization (BIO) is promising to crack down on “bad actors” that increase drug prices “dramatically”—in part by expelling member companies that carry out the sky-high hikes.

Health IT vendor Cerner has revealed a new challenge that asks developers to improve patients’ access to EHRs, according to a company news release.

Dubbed the 2019 code App Challenge, the contest encourages participants to build apps on Cerner’s platforms.

Whether you’re starting a business, relocating one, or just moving to live and work, there are endless reasons for why Maryland is the top state to relocate to. The BioHealth Capital Region continues to climb the GEN’s annual ranking of the nation’s top biopharma clusters, and was ranked fourth in 2018. There are many factors that make Maryland a great place to headquarter your BioHealth company. Biotech and life science companies are high-risk high expense ventures, and the location of your company is key to its success.

Governor Ralph Northam today announced $2.51 million in funding in support of 41 Commonwealth Research Commercialization Fund (CRCF) awards. The projects represent exciting advancements in five industries: clean energy, cybersecurity, data analytics, life sciences, and unmanned systems.

Johns Hopkins has ranked among the top 10 patent-earners since 2014.

Biotechnology venture capital firm Third Rock Ventures has raised $770m for its fifth fund, a sign that investor interest in funding early-stage science continues unabated despite volatile public markets.

The investment vehicle, the largest ever raised by Third Rock in its 12-year history, will support investments in 10 to 12 companies. The Boston-based firm's new fund came together quickly.

The Georgia Tech alum is the first Spanish-born president of an American university.

The U.S. Small Business Administration (SBA) has announced the fifth round of its Growth Accelerator Fund Competition to recognize innovative accelerators, including incubators, co-working startup communities or other similar models, to compete for prizes of $50,000 each for a total of $3 million.

Emergent BioSolutions CEO Robert Kramer Sr. sits down with Yahoo Finance's Dan Roberts, Melody Hahm and Myles Udland on "YFi AM" to discuss the fight over drug pricing and hear how the biopharmaceutical company is seeking to make Narcan, a life-saving drug that blocks the effects of an opioid overdose, more affordable and accessible.

Although the recent $110 million funding round for Thrive Earlier Detection Corp. was impressive — it is certainly not the biggest we've seen around Maryland to date.

The two health care organizations have been investing separately in health technology and companies for several years.

Altimmune, Inc. (ALT), a clinical-stage biotechnology company, today announced that it has received additional patent protection for its HepTcell and ALT-702 programs in the United States.

Johns Hopkins University is planning a bold new approach to career development for students and alumni that includes opening three new administrative offices, launching new initiatives, and better integrating career and life design into the academic and co-curricular experience of all Hopkins students and postdocs.

For augmenting readability, The Research Insights has added a fresh market study, titled Vaccines Market to its flared database. The report has been put together in a chapter-wise arrangement, by separating required illustrations transversely. This report is an expedient tool to get responses to some of the queries that hold significance for the growth of the Vaccines Market during the forecast period. The evidence in the report was congregated from qualified organizations & dependable sources and was further authenticated by industry specialists for increased integrity

The Biotechnology Innovation Organization (BIO) released “Transforming Ideas into Advances: Best Practices in State and Regional Bioscience Economic Development Initiatives” today at the 2019 BIO International Convention.

The fifth edition of the Best Practices Guide is the bioscience industry’s leading comprehensive analysis of state legislative and regulatory initiatives in support of economic development.